<DOC>
	<DOCNO>NCT01103648</DOCNO>
	<brief_summary>Ezetimibe specifically block absorption dietary biliary cholesterol plant sterol . Synergism ezetimibe-statin therapy LDL-cholesterol demonstrate , data concern pleiotropic effect combination controversial . We test hypothesis combination simvastatin ezetimibe would induce improvement inflammatory status , reflect leukocyte count CRP , IL-6 TNF-a level . This open-label trial evaluate whether combination result synergistic effect pro-inflammatory status pre-diabetic subject . Fifty pre-diabetic subject randomly assign one 2 group , one receiving ezetimibe ( 10 mg/d ) , , simvastatin ( 20 mg/d ) 12 week , follow additional 12-week period combine therapy .</brief_summary>
	<brief_title>Effect Simvastatin Ezetimibe Lipid Inflammation</brief_title>
	<detailed_description>Long-term benefit statin prevention cardiovascular event consistently show several population . It demonstrate , particular regard subject high risk , low LDL-cholesterol level , low incidence cardiovascular outcome . Beneficial effect statin attribute lipid-lowering ability well additional benefit . The so-called pleiotropic effect low grade inflammation status describe subset subject different cardiovascular profile . The common inflammatory marker use clinical practice high-sensitivity C-reactive protein ( CRP ) level , number others also investigate . Disturbances glucose metabolism accompany insulin resistance pro-inflammatory condition may accelerate atherosclerosis . Diabetic population high cardiovascular risk strict control lipoprotein concentration recommend . Several recent study show efficacy statin primary secondary prevention cardiovascular event diabetic population . The goal 100 mg/dL LDL-cholesterol may elevate subject high risk target 70 mg/dl suggest . High statin dos may necessary , increase adverse effect . Given statin monotherapy may insufficient desirable reduction LDL level , combination lipid-lowering agent become frequent clinical practice . In particular , statin ezetimibe combination show effective reduce total LDL cholesterol level . Ezetimibe specific cholesterol absorption inhibitor act brush border small intestine , block absorption dietary biliary cholesterol plant sterol , result intracellular cholesterol depletion via Niemann-Pick C1-like transporter . Adding ezetimibe statin therapy induce 15 % reduction LDL level compare 6 % achieve double dose statin . Data concern pleiotropic effect combination controversial . One study , CRP level use inflammatory marker , find combination simvastatin ezetimibe produce incremental effect lower CRP , independently improvement lipoprotein concentration . Although study confirm finding , far know , data regard simvastatin-ezetimibe combination induced-changes serum interleukin-6 ( IL-6 ) tumor necrosis factor alpha ( TNF-a ) level lack . We test hypothesis combination would induce improvement inflammatory status , reflect leukocyte count CRP , IL-6 TNF-α level . Therefore , study evaluate whether combination lipid-lowering effect low-to-moderate dose simvastatin ezetimibe also result synergistic effect reduce pro-inflammatory status pre-diabetic subject mild-to-moderate hypercholesterolemia . Subjects Methods : Participants select Federal University São Paulo outpatient clinic . The study approve institutional ethical committee participant provide write informed consent . Eligible subject men woman , age 18 75 year , body mass index ( BMI ) range 25 40 kg/m2 pre-diabetes ( impaired glucose tolerance impair fast glucose ) . Entry criterion require triglyceride level ≤ 350 mg/dl LDL cholesterol ≤ 200 mg/dl , stable blood pressure evidence cardiovascular , hepatic renal disease . Subjects take anti-inflammatory agent others interfere lipid glucose metabolism . Eligible participant recruit June 2005 May 2006 . Two-hundred-ninety subject weight excess , without family history diabetes , screen interventional protocol 50 impair glucose tolerance ( IGT ) impair fast glucose ( IFG ) randomly assign 2 group would receive ezetimibe 10 mg/d ( n = 25 ) simvastatin 20 mg/d ( n = 25 ) , precede 2-week run-in period . Monotherapies maintain 12 week ; thereafter drug combine group additional 12-week period . All participant receive individual counseling healthy lifestyle monthly visit . Treatment discontinue prematurely transaminases exceed 3 time upper limit reference creatine phosphokinase ( CPK ) 10 time , subject meet criterion . One ezetimibe group drop due non-compliance . Baseline , 12-week 24-week blood sample draw morning , 12-hour fast , glucose , lipid profile , include apolipoprotein A-I B , leukocyte count inflammatory marker make . A LDL-cholesterol goal 100 mg/dl use present study ( 8,22 ) . Laboratory analysis : Plasma glucose , transaminase , CPK creatinine determine routine method . Serum lipid level ( total cholesterol , HDL-cholesterol , triglyceride ) analyze commercially available test ( Roche Diagnostics GmbH , Mannheim , Germany ) . Blood sample store -20ºC determination apolipoproteins inflammatory marker . Apolipoprotein A-I B measure immunoturbidimetry ( Olympus Life Material Science Europa GmbH , Lismeeham , Ireland ) , intra-assay coefficient variability ( CV ) 1.26-1.30 % 0.93-1.17 % respectively , inter-assay CV 1.43-1.55 % 1.10-1.46 % , respectively . High-sensitivity CRP ( Immulite - DPC , Los Angeles , CA , USA ) , TNF-α IL-6 ( Immulite - Euro/DPC , Llanberis , Gwynedd , UK ) determine chemiluminescent immunometric assay . The sensitivity CRP assay 0.01 mg/dL ( intra-assay CV 4.2-6.4 % inter-assay CV 4.8-10 % ) , TNF-α assay 1.7 pg/mL ( intra-assay CV 2.6-3.6 % , inter-assay CV 4.0-6.5 % ) IL-6 assay 2.0 pg/mL ( intra-assay CV 3.5-6.2 % , inter-assay CV 5.1-7.5 % ) . Statistical analysis : Data express mean value standard error deviation . Unpaired Student 's test use compare group baseline chi-square ass difference qualitative data . One-way ANOVA repeat measure use evaluate effect drug time compare data group subject accord type therapy . Pairwise contrast make compare least-square mean estimate , P value adjust multiple comparison use Bonferroni Holm method . The level significance set P &lt; 0.05 . Correlation variable test Pearson coefficient , also employ ass whether change variable time correlate . Data analysis perform use Statistical Analysis System software , version 8.2 ( SAS Institute , Cary , NC ) .</detailed_description>
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Prediabetic State</mesh_term>
	<mesh_term>Glucose Intolerance</mesh_term>
	<mesh_term>Hypolipidemic Agents</mesh_term>
	<mesh_term>Ezetimibe</mesh_term>
	<mesh_term>Simvastatin</mesh_term>
	<mesh_term>Ezetimibe , Simvastatin Drug Combination</mesh_term>
	<mesh_term>Hydroxymethylglutaryl-CoA Reductase Inhibitors</mesh_term>
	<criteria>Both sex , age 18 75 year , body mass index range 25 40 kg/m2 prediabetes ( impaired glucose tolerance impair fast glucose ) . Blood triglyceride concentration &gt; 350 mg/dl LDL cholesterol &gt; 200 mg/dl , unstable blood pressure , clinical evidence cardiovascular , hepatic renal disease , use antiinflammatory agent others interfere lipid glucose metabolism .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2007</verification_date>
	<keyword>Prediabetes</keyword>
	<keyword>Statin</keyword>
	<keyword>Ezetimibe</keyword>
	<keyword>Pleiotropic effect</keyword>
	<keyword>Cardiometabolic risk</keyword>
</DOC>